A Study with L19TNF in Combination with Lomustine in Patients with Glioblastoma At Progression or Recurrence

Recruiting

Phase 2

L19TNF & LomustineA Study with L19TNF in Combination with Lomustine in Patients with Glioblastoma At Progression or Recurrence

Sponsor:

Philogen S.p.A.

Code:

NCT06336291

Conditions

Glioblastoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

L19TNF

Lomustine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Philogen S.p.A. on 2025-03-25.